gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Coagulation factor X

factor Xa, factor X, F10, prothrombinase
This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, HAD, Thromboplastin, AGE, V1a
Papers using factor Xa antibodies
Signaling pathways controlling second heart field development
Uversky Vladimir N., In PLoS ONE, 2008
... After 3 days of incubation oocytes were incubated with 1 µg/mL primary rat monoclonal anti-HA antibody (clone 3 F10, Roche, Mannheim, Germany) and subsequently with secondary, HRP-conjugated goat anti-rat IgG (H&L) antibody (1∶1000, Cell Signaling Technology, MA, USA) ...
Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells.
Combs Colin, In PLoS ONE, 2006
... The culture medium consisted of Dulbecco's modified Eagle's medium (DMEM)-F10 (Gibco, Life Technologies, Breda, The Netherlands), supplemented ...
Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line
Sakamoto-Hojo Elza Tiemi et al., In Genetics and Molecular Biology, 2005
... Cells were routinely grown in Dulbecco's modified Eagle's medium (DMEM) + F10 (1:1) (Sigma Aldrich, St ...
Avoli Massimo, In PLoS ONE, 2000
... After mechanical dissociation, single cells were resuspended in F10 medium, supplemented with 10% fetal calf serum (FCS, Life Technologies Ltd, Milano, Italy) and ...
more suppliers
Papers on factor Xa
The problem of atrial fibrillation in patients with chronic kidney disease.
Rysz et al., Łódź, Poland. In Curr Vasc Pharmacol, Feb 2016
Moreover, renal function should be evaluated before initiation of direct thrombin or factor Xa inhibitors and re-evaluated when clinically indicated and at least annually.
Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro.
Bae et al., Kyŏngsan, South Korea. In Arch Pharm Res, Feb 2016
We tested the effect of pelargonidin and its glucoside-conjugated form, pelargonidin-3-glucoside, on the clotting times, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT), and the activities and productions of thrombin and activated factor X (FXa).
How the Linker Connecting the Two Kringles Influences Activation and Conformational Plasticity of Prothrombin.
Di Cera et al., Saint Louis, United States. In J Biol Chem, Feb 2016
Furthermore, activation by prothrombinase takes place without preference along the prethrombin-2 (cleavage at R271 first) or meizothrombin (cleavage at R320 first) pathways.
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population.
So et al., Greensboro, United States. In Cardiol Ther, Feb 2016
The two classes of DOACs and the drugs they are comprised of are factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran).
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Crowther et al., Hamilton, Canada. In N Engl J Med, Jan 2016
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs.
SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis.
Valenzuela et al., Belo Horizonte, Brazil. In Sci Rep, Dec 2015
Both rSALO and SGH inhibited C4b deposition and cleavage of C4. rSALO, however, did not inhibit the protease activity of C1s nor the enzymatic activity of factor Xa, uPA, thrombin, kallikrein, trypsin and plasmin.
The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis.
Ward et al., Melbourne, Australia. In Hematol Rep, Dec 2015
In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa (AFXa) for dose adjustment.
Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.
Buck, Charlottesville, United States. In J Pediatr Pharmacol Ther, Nov 2015
It is more expensive than heparin, but the cost may be offset by reductions in the costs associated with heparin use, including anti-factor Xa testing and the need for administration of antithrombin.
A New Generation of Antiplatelet, and Anticoagulant Medication and the Implications for the Dental Surgeon.
Johnston, In Dent Update, Nov 2015
Recently, new generations of drugs have emerged which are becoming increasingly common, including direct thrombin inhibitors, factor X inhibitors and a new class of oral thienopyridines.
[Identification of Target Extracellular Proteases--Activators of Proteins of Haemostasis System Produced by Micromycetes Aspergillus ochraceus and Aspergillus terreus].
Egorov et al., In Bioorg Khim, Sep 2015
Was discovered, that A. ochraceus proteases have a direct influence on protein C and coagulation factor X, and A. terreus proteases causes their activation indirectly through kallikrein system stimulation.
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.
Granger et al., Amsterdam, Netherlands. In Lancet, Aug 2015
In the past decade, oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is the first protein in the final common pathway to the activation of thrombin.
A Newly-Discovered Mutation in the RFX6 Gene of the Rare Mitchell-Riley Syndrome.
Dandan et al., In J Clin Res Pediatr Endocrinol, Feb 2015
However, the genetic mutation in RFX6 (regulatory factor X on chromosome 6) was only detected in babies who had diabetes, making it different from the previously known mutations for the disease.
New approaches to inhibiting platelets and coagulation.
Bhatt et al., Boston, United States. In Annu Rev Pharmacol Toxicol, 2014
Oral anticoagulation has advanced with the use of direct thrombin and factor Xa inhibitors that do not require therapeutic monitoring.
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Berge et al., Oslo, Norway. In Jama, 2014
CLINICAL QUESTION: Is treatment with factor Xa inhibitors associated with better efficacy and safety compared with the vitamin K antagonist warfarin for preventing strokes or other systemic embolic events in patients with atrial fibrillation?
Treatment of venous thromboembolism.
Rodger et al., Ottawa, Canada. In Jama, 2014
In general, DVT and PE patients require 3 months of treatment with anticoagulants, with options including LMWH, vitamin K antagonists, or direct factor Xa or direct factor IIa inhibitors.
Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.
Francischetti et al., Rockville, United States. In Arterioscler Thromb Vasc Biol, 2012
Lufaxin belongs to a novel family of slow-tight FXa inhibitors/PAR-2 receptor inhibitors with antiinflammatory/antithrombotic properties.
Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalyzed cleavage rates at this site and cofactor function.
Fay et al., Rochester, United States. In J Biol Chem, 2012
Data show that the capacity for FXa to activate FVIII variants where cleavage at Arg(336) was accelerated due to flanking sequence replacement showed marked reductions in peak activity.
Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
Kisiel et al., Białystok, Poland. In Thromb Res, 2012
localization of PZ/ZPI and FX in colon cancer cells indicates that PZ/ZPI may contribute to anticoagulant events at the tumor site.
Identification of exosite residues of factor Xa involved in recognition of PAR-2 on endothelial cells.
Rezaie et al., Saint Louis, United States. In Biochemistry, 2012
the molecular determinants of the specificity of FXa interaction with PAR-2
Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase.
Fay et al., Rochester, United States. In Biochemistry, 2012
Mutagenesis of residues within FVIII sequence, Thr2012 and Phe2014, contributes to the FX binding interaction and to the catalytic efficiency of FXase for factor X.
More papers using factor Xa antibodies
Protein C activation on endothelial cells by prothrombin activation products generated in situ: Meizothrombin is a better protein C activator than α-thrombin
Kalafatis Michael et al., In Biochemistry, 1995
... -(3-ethyl-1,5-pentanediyl) amide (DAPA), human factor Xa, human α-thrombin, and human prothrombin were purchased from Haematologic Technologies Inc ...
Expression of the ogt gene in wild-type and ada mutants of E.coli
Margison Geoffrey P. et al., In Nucleic Acids Research, 1988
... Vent polymerase, restriction enzymes, factor Xa and amylose-resin were purchased from New England Biolabs.
share on facebooktweetadd +1mail to friends